Vor Biopharma (NYSE:VOR - Get Free Report)'s stock had its "outperform" rating reissued by analysts at Wedbush in a research report issued on Tuesday, Benzinga reports. They presently have a $11.00 target price on the stock. Wedbush's target price would indicate a potential upside of 485.11% from the stock's current price.
Other research analysts have also recently issued research reports about the stock. HC Wainwright reiterated a "buy" rating and issued a $17.50 target price on shares of Vor Biopharma in a research note on Thursday, March 21st. JMP Securities restated a "market outperform" rating and issued a $12.00 price objective on shares of Vor Biopharma in a research report on Friday, March 22nd. Oppenheimer restated an "outperform" rating and issued a $15.00 price objective (down previously from $17.00) on shares of Vor Biopharma in a research report on Thursday, March 21st. Finally, Stifel Nicolaus dropped their price objective on shares of Vor Biopharma from $15.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, March 21st. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average target price of $13.50.
Read Our Latest Stock Report on Vor Biopharma
Vor Biopharma Price Performance
Shares of NYSE:VOR traded up $0.06 during trading on Tuesday, reaching $1.88. The stock had a trading volume of 209,626 shares, compared to its average volume of 293,527. Vor Biopharma has a 52 week low of $1.62 and a 52 week high of $5.70. The business's 50-day moving average price is $2.04 and its 200 day moving average price is $2.11. The stock has a market capitalization of $128.25 million, a PE ratio of -1.06 and a beta of -0.36.
Vor Biopharma (NYSE:VOR - Get Free Report) last posted its earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.10. Analysts forecast that Vor Biopharma will post -1.34 EPS for the current year.
Institutional Trading of Vor Biopharma
An institutional investor recently raised its position in Vor Biopharma stock. Exchange Traded Concepts LLC boosted its holdings in shares of Vor Biopharma Inc. (NYSE:VOR - Free Report) by 34.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 60,170 shares of the company's stock after acquiring an additional 15,258 shares during the period. Exchange Traded Concepts LLC owned 0.09% of Vor Biopharma worth $135,000 as of its most recent filing with the SEC. 97.29% of the stock is owned by institutional investors and hedge funds.
Vor Biopharma Company Profile
(
Get Free Report)
Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
Further Reading
Before you consider Vor Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.
While Vor Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
